GLP-1 drugs and sleep apnoea: the survey

A pan-European survey published on 25 August 2026 in Pulmonology (PMID 42639925) asked 24 sleep-medicine centres how they are using GLP-1 receptor agonists in clinical practice for obstructive sleep apnoea (OSA). The headline finding: practice is fragmented, guidance is thin, and most centres have not yet agreed on when to adjust CPAP therapy for patients who lose weight on these drugs^[1].

What the 24-centre survey found

The survey, conducted through the European Sleep Apnoea Database (ESADA) network and led by Testelmans D and colleagues, found that only 42% of participating centres allow sleep physicians to initiate GLP-1 therapy^[1]. In most centres, prescribing falls to endocrinologists or obesity-medicine specialists, with sleep medicine playing a secondary role.

On the question of when a weight-loss response becomes clinically meaningful for OSA, the survey found more consensus: 61% of centres set a threshold of greater than 10% body-weight reduction before recommending a repeat diagnostic sleep study^[1]. Yet despite that stated threshold, proactive airway-pressure adjustments in patients who are losing weight on GLP-1 treatment remain infrequent, reported by only 14% of centres.

The gap between the 61% who recognise that significant weight loss warrants reassessment and the 14% who act on that recognition by adjusting PAP settings is the core unmet-needs finding. Patients may be over-pressured on CPAP while their OSA severity improves, and the survey suggests this is not being caught systematically.

Why tirzepatide is the drug behind the survey

The survey was prompted in part by the US regulatory step that gave GLP-1 medicines a formal foothold in sleep medicine. In December 2024 the FDA approved tirzepatide (Zepbound) specifically for moderate-to-severe obstructive sleep apnoea in adults with obesity, the first approval of a pharmacological agent for OSA in the US.

The trial supporting that approval, SURMOUNT-OSA (Malhotra A et al., NEJM 2024, PMID 38912654), enrolled adults with a mean baseline apnoea-hypopnoea index (AHI) of around 50 events per hour and a mean BMI near 39. In Trial 1 (no baseline PAP use), tirzepatide reduced AHI by a mean of 25.3 events per hour versus 5.3 on placebo. In Trial 2 (baseline PAP users), the reduction was 29.3 events per hour versus 5.5 on placebo^[2]. Improvements in hypoxic burden, CRP, and blood pressure followed.

The EMA has not authorised tirzepatide specifically for OSA. Mounjaro is approved in the EU for type-2 diabetes and for weight management in adults with obesity or overweight and at least one weight-related comorbidity (OSA is listed as one such comorbidity, but the OSA indication itself is not separately authorised). Full EU approval status is on the tirzepatide page.

The mechanism: weight loss does the work

A 2026 narrative review in Nature and Science of Sleep (Zhang X et al., PMID 42591103) covering incretin-based therapies in obesity-related OSA found that the available mechanistic evidence points to weight-loss-mediated anatomical unloading as the primary pathway^[3]. GLP-1 receptor agonists and dual GIP/GLP-1 agonists do not appear to act directly on upper-airway tone. The AHI improvement tracks the weight reduction.

This matters clinically because it means the magnitude of OSA benefit depends on how much weight a patient actually loses, and that weight loss varies between individuals. A patient who loses 5% body weight will see a different AHI change than one who loses 18%. The survey's 10% weight-loss threshold for repeat sleep testing is a working consensus number, not a regulatory standard.

What the survey says clinicians need

Testelmans et al. conclude that harmonised clinical guidance and coordinated multidisciplinary protocols are the main unmet needs^[1]. Most clinicians in the survey already recommend ongoing diagnostic sleep studies after GLP-1 initiation, which is consistent with SURMOUNT-OSA's design. The gap is on the action side: systematically adjusting PAP pressure as OSA severity changes.

The survey does not report patient-level outcomes. It is a practice-pattern study, not a trial, so it cannot say whether the gap in PAP adjustments is causing harm. That question requires prospective data, which does not yet exist for this indication and drug class.

What is not yet settled

The ESADA survey covers 24 European centres. How representative that sample is of the broader sleep-medicine landscape across the EU is a limitation the authors acknowledge. The pan-European footprint is real, but 24 centres is a small number for a continent with hundreds of accredited sleep units.

Long-term durability of the AHI benefit is also an open question. SURMOUNT-OSA ran for 52 weeks. Whether AHI improvements persist for multiple years, or whether they track weight regain (as seen in the STEP-4 discontinuation data for semaglutide), has not been tested.

For readers tracking this space, the practical position right now is this: GLP-1 receptor agonists have trial-level evidence for OSA benefit through weight loss. In the US, tirzepatide has a specific regulatory approval for it. In the EU, sleep physicians are integrating GLP-1 therapy without a harmonised protocol, and the survey is the first systematic map of how that integration looks. More guidance is expected as prescribing volumes grow. See the tirzepatide overview for the full regulatory and clinical picture.